Compared with the control group and the monotherapy group, the tumors in the combined TG-101,209 treatment group were significantly smaller, the proliferation rate and activity of tumor cells were reduced, and there was a significant increase in functional CD8 + T cells and a substantial reduction in CD8 + PD1 + T cells (Fig. 11). The gene discussed is CD8A; the disease is neoplasm.